Nivolumab,Ipilimumab,Cabozantinib,Sunitinib
BMS,Pfizer
['nivolumab', 'sunitinib', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'al 101', 'renal,(-adrenal)', 'check,mate,9er', 'biomarker', 'cabo ', 'nivo', 'bristol', 'marker ']
amazing talk md toni k. choueiri showed us the biomarker analysis from the phase 3 checkmate 9er trial of nivolumab + cabozantinib vs sunitinib for rcc suggesting that key determinants of response to anti pd-1 v anti pd-l1 therapies may differ #ascogu23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.